Brief: EMA's CHMP Recommended Granting Marketing Authorisation For Moderna's Mnexspike
12/12/2025 15:11
Dec 12 (Reuters) - EMA's CHMP: EMA'S CHMP: RECOMMENDED GRANTING MARKETING AUTHORISATION FOR MNEXSPIKE, FOR PREVENTION OF COVID-19 IN PEOPLE FROM 12 YEARS OF AGE EMA'S CHMP: RECOMMENDED CHANGE TO EXTEND USE OF MOUNJARO FOR TREATMENT OF A TYPE OF TYPE 2 DIABETES EMA'S CHMP: EXDENSUR (DEPEMOKIMAB) RECEIVED A POSITIVE OPINION EMA'S CHMP: RECOMMENDS EXTENSION OF THERAPEUTIC INDICATION FOR UPLIZNA EMA'S CHMP: RECOMMENDS EXTENSION OF THERAPEUTIC INDICATION FOR NUCALA EMA'S CHMP: ADOPTED A POSITIVE OPINION FOR MYQORZO FOR TREATMENT OF ADULTS WITH OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY EMA'S CHMP: CONCLUDES REFERRAL FOR MELATOMED, RECOMMENDS MARKETING AUTHORISATION CAN BE GRANTED EMA'S CHMP: RECOMMENDED EXTENSIONS OF INDICATION FOR AREXVY, ASPAVELI, DOVPRELA, ELUCIREM, EYLEA, NUCALA, RECARBRIO, SIMPONI, UPLIZNA, VUEWAY Further company coverage: MRNA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Regeneron Pharmaceuticals
See all newsLilly, Regeneron selected for US program to review new manufacturing plants faster (updated)
FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports
Brief: Eli Lilly, Regeneron Among First Companies Selected For FDA Initiative To Speed Review Of New Manufacturing Facilities - CNBC
Brief: Cemdisiran Regulatory Submissions Accepted For Review By FDA And EMA For The Treatment Of Generalized Myasthenia Gravis (Gmg)
AbbVie sharpens immunology focus with $10.9 billion Apogee deal (updated)